Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Retatrutide (LY3437943) in Type 2 Diabetes
NCT04867785Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of retatrutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started May 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04867785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867785.